Little Green Pharma Says 12-Month Medicinal Cannabis Study Results Showed Clinically Meaningful Improvements

MT Newswires Live
04-04

Little Green Pharma (ASX:LGP) said the 12-month follow-up results of the Quality of Life Evaluation Study (QUEST) initiative, showed clinically meaningful improvements across all patients for health-related quality of life, fatigue, and sleep, as well as clinically meaningful reductions in anxiety, pain, depression and sleep disorders in patients, according to a Friday Australian bourse filing.

The study is investigating the effect of medicinal cannabis on patient quality of life and chronic conditions. The firm exclusively supplied the medicinal cannabis products in the study.

The University of Sydney led the study. The 12-month findings have been peer-reviewed and published in the open-access journal, PLOS One.

The next phase of the initiative is a global study led by Curtin University, which is recruiting patients.

Study participants were aged between 18 and 97 years, and 63% of them were female. Chronic musculoskeletal pain and chronic neuropathic pain at 63%, sleep disorders at 23%, and generalized anxiety disorder and depression at 11% were the most reported conditions.

The participants in the study used oral medicinal cannabis according to the study protocol and had previously experienced unsuccessful results with other pharmaceutical treatments.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10